Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.55 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.55 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | QDPR | P09417 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50923 | 0.98 | QDPR (0.67) | QDPRHTR6KDM4ELMNAPOLB | |
| SCHEMBL16862164 | 0.98 | QDPR (0.67) | QDPRHTR6KDM4ELMNAPOLB | |
| Bromide SCHEMBL11557389 | 0.96 | QDPR (0.65) | QDPRHTR6KDM4ELMNAPOLB | |
| Ammonia Solution, Strong SCHEMBL15875021 | 0.96 | QDPR (0.65) | QDPRHTR6KDM4ELMNAPOLB | |
| SCHEMBL13898494 | 0.94 | QDPR (0.68) | QDPRHTR6KDM4ELMNAPOLB | |
| Hydrochloric Acid SCHEMBL19717522 | 0.94 | QDPR (0.62) | QDPRHTR6KDM4ELMNAPOLB | |
| SCHEMBL16565762 | 0.86 | QDPR (0.53) | QDPRNPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL6517404 | 0.86 | QDPR (0.50) | QDPRHTR6KDM4ELMNAPOLB | |
| SCHEMBL8264178 | 0.82 | QDPR (0.59) | QDPRSLC6A4 | |
| SCHEMBL7369176 | 0.82 | QDPR (0.72) | QDPRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115735857-A | Construction method of animal model of Parkinson's disease | 江苏珂玛麒生物科技有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-122075454-A | Smell composition for improving non-motor symptoms of parkinsonism, multi-layer controlled release olfactory training component and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089753-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089751-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026088039-A1 | ENCAPSULATED APOMORPHINE COMPOSITIONS | MASSEY VENTURES LIMITED (NZ) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108582-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108581-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-5674521-A | DRUG DELIVERY SYSTEM COMPRISING POLYMER GEL NETWORK INCLUDING BIOLOGICALLY ACTIVE SOLUTE, SALT, LOADING POLYMER; REDUCED LOSS OF ACTIVITY | UNIVERSITY OF CINCINNATI (US) | 1997-10-07 | — | — | US | disclosed |
| US-5603955-A | GEL NETWORK; PROTECTIVE POLYMER; PROTECTANT SALT | UNIVERSITY OF CINCINNATI (US) | 1997-02-18 | — | — | US | disclosed |
| WO-1997000275-A2 | RESPONSIVE POLYMER NETWORKS AND METHODS OF THEIR USE | GEL SCIENCES, INC. (US) | 1997-01-03 | — | — | WO | disclosed |
| EP-0749311-A1 | PHARMACEUTICAL COMPOSITION OF INDENE DERIVATIVES FOR REGULATING APOPTOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996021449-A1 | PHARMACEUTICAL COMPOSITION OF INDENE DERIVATIVES FOR REGULATING APOPTOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-18 | — | — | WO | disclosed |
| EP-0584220-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992020325-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0243903-B1 | Optionally substituted 1-(omega[bis(phenyl)-alcoxy]-alkyl)-4-(alkenyl)piperazines and -4-(alkynyl)piperazines, process for their preparation and medicines containing them | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1992-03-18 | — | — | EP | disclosed |
| US-4874765-A | 1,4-Disubstituted piperazines having dopaminergic activity | RICHTER GEDEON VEGYESZETI GYAR (HU) | 1989-10-17 | — | — | US | disclosed |
| EP-0243903-A1 | Optionally substituted 1-(omega[bis(phenyl)-alcoxy]-alkyl)-4-(alkenyl)piperazines and -4-(alkynyl)piperazines, process for their preparation and medicines containing them | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108581-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | HTT, CLN6, HDAC6 | HTR6 304/4885HTR1A 931/4885SLC6A4 99/4885 |
| US-20260108582-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | SNCA, CLN6, PRNP | HTR6 353/4885HTR1A 497/4885SLC6A4 37/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | HTR6 891/4885HTR1A 1769/4885SLC6A4 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.